GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of 42 per equity share.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals reported strong FY25 results with standalone revenue from operations growing about 9.3% to Rs. 3,723 crore (vs Rs. 3,407 crore last year). Standalone profit after tax jumped roughly 57% to Rs. 919 crore (vs Rs. 585 crore), boosted by the absence of last year's one-time VRS (Voluntary Retirement Scheme) charge of Rs. 163 crore. The board recommended a final dividend of Rs. 42 per share (face value Rs. 10), up 31% from Rs. 32 in FY24, pending shareholder approval at the 100th AGM on June 27, 2025. Q4 standalone revenue grew about 6% to Rs. 966 crore with profit rising about 35% to Rs. 260 crore. The company also re-appointed Dr. Sunita Maheshwari as Independent Director for a second 3-year term and appointed Parikh & Associates as Secretarial Auditor for 5 years. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion.
Sharp profit growth, higher dividend, and clean audit opinion are positive for shareholders; the stock may see supportive sentiment, though much of the PAT jump reflects the non-repeat of last year's VRS cost rather than pure operational acceleration.